Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 4, 2009, Pages 1115-1122

  Yadav, Manish ^a,b   Rao, Rajasekhar ^a   Kurani, Hemal ^a   Singhal, Puran ^a   Goswami, Sailendra ^a   Shrivastav, Pranav S ^b  

^a Veeda Clinical Research India   (India)

^b GUJARAT UNIVERSITY   (India)

Author keywords

Bioequivalence; High throughput; Lopinavir; Ritonavir; UPLC ESI MS MS

Indexed keywords

AMMONIUM FORMATE; FORMIC ACID; LOPINAVIR; METHANOL; RITONAVIR;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DIET RESTRICTION; DRUG DETERMINATION; DRUG PROTEIN BINDING; ELECTROSPRAY; ELECTROSPRAY MASS SPECTROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; INDIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE REACTION MONITORING; NORMAL HUMAN; PARAMETER; PLASMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REPRODUCIBILITY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDITY;

ADULT; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; INDIA; MALE; PYRIMIDINONES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RITONAVIR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERAPEUTIC EQUIVALENCY;

EID: 62749206666     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.02.010     Document Type: Article

References (40)

1. Gallant J.E. J. Clin. Virol. 25 (2002) 317-333
2. Clevenbergh P., Mouly S., Sellier P., Badsi E., Cervoni J., Vincent V., Trout H., and Bergmann J.F. Curr. HIV Res. 2 (2004) 309-321
3. Boffito M., Acosta E., Burger D., Fletcher C.V., Flexner C., Garaffo R., Gatti G., Kurowski M., Perno C.F., Peytavin G., Regazzi M., and Back D. Antivir. Ther. 10 (2005) 375-392
4. von Hentig N. Drugs Today (Barc.) 43 (2007) 221-247
5. Martin T.M., Morse G.D., Kurpewski J., Difrancesco R., Caliendo A.M., Flanigan T.P., and Tashima K.T. AIDS 20 (2006) 1085-1087
6. Porche D.J. J. Assoc. Nurses AIDS Care 12 (2001) 101-104
7. Cvetkovic R.S., and Goa K.L. Drugs 63 (2003) 769-802
8. Azoulay S., Nevers M.C., Creminon C., Heripret L., Garraffo R., Durant J., Dellamonica P., Grassi J., Guedj R., and Duval D. J. Immunol. Methods 295 (2004) 37-48
9. DiFrancesco R., DiCenzo R., Vicente G., Donnelly J., Martin T.M., Colon L.A., Schifito G., and Morse G.D. J. Pharm. Biomed. Anal. 44 (2007) 1139-1146
10. Marsh K.C., Eiden E., and McDonald E. J. Chromatogr. B 704 (1997) 307-313
11. Granda B.W., Giancarlo G.M., von Moltke L.L., and Greenblatt D.J. J. Pharmacol. Toxicol. Methods 40 (1998) 235-239
12. Hoetelmans R.M.W., van Essenberg M., Profijt M., Meenhorst P.L., Mulder J.W., and Beijnen J.H. J. Chromatogr. B 705 (1998) 119-126
13. Akeb F., Ferrua B., Creminon C., Roptin C., Grassi J., Nevers M.C., Guedj R., Garraffo R., and Duval D. J. Immunol. Methods 263 (2002) 1-9
14. Marzolini C., Begiun A., Telenti A., Schreyer A., Buclin T., Biollaz J., and Decosterd L.A. J. Chromatogr. B 774 (2002) 127-140
15. Frappier S., Breilh D., Diarte E., Ba B., Ducint D., Pellegrin J.L., and Saux M.C. J. Chromatogr. B 714 (1998) 384-389
16. Albert V., Modamio P., Lastra C.F., and Marino E.L. J. Pharm. Biomed. Anal. 36 (2004) 835-840
17. Langmann P., Klinker H., Schirmer D., Zilly M., Bienert A., and Richter E. J. Chromatogr. B 735 (1999) 41-50
18. Janoly A., Bleyzac N., Favetta P., Gagneu M.C., Bourhis Y., Coudray S., Oger I., and Aulagner G. J. Chromatogr. B 780 (2002) 155-160
19. Fin B., and Stewart J.T. J. Pharm. Biomed. Anal. 30 (2002) 955-960
20. Ray J., Pang E., and Carey D. J. Chromatogr. B 775 (2002) 225-230
21. Usami Y., Oki T., Nakai M., Sagisaka M., and Kaneda T. Chem. Pharm. Bull. 51 (2003) 715-718
22. van Heeswijk R.P.G., Hoetelmans R.M.W., Harms R., Meenhorst P.L., Mulder J.W., Lange J.M.A., and Beijnen J.H. J. Chromatogr. B 719 (1998) 159-168
23. Hugen P.W.H., Verweij-van Wissen C.P.W.G.M., Burger D.M., Wuis E.W., Koopmans P.P., and Hekster Y.A. J. Chromatogr. B 727 (1999) 139-149
24. Yamada H., Kotaki H., Nakamura T., and Iwamoto A. J. Chromatogr. B 755 (2001) 85-89
25. Sarasa-Nacenta M., Lopez-Pua Y., Mallolas J., Blanco J.L., Gatell J.M., and Carne X. J. Chromatogr. B 757 (2001) 325-332
26. Justesen U.S., Pedersen C., and Klitgaard N.A. J. Chromatogr. B 783 (2003) 491-500
27. Verbesselt R., Wijngaerden E.V., and de Hoon J. J. Chromatogr. B 845 (2007) 51-60
28. Chi J., Jayewardene A.L., Stone J.A., Motoya T., and Aweeka F.T. J. Pharm. Biomed. Anal. 30 (2002) 675-684
29. Frerichs V.A., DiFrancesco R., and Morse G.D. J. Chromatogr. B 787 (2003) 393-403
30. Rouzes A., Berthoin K., Xuereb F., Djabarouti S., Pellegrin I., Pellegrin J.L., Coupet A.C., Augagneur S., Budzinski H., Saux M.C., and Breilh D. J. Chromatogr. B 813 (2004) 209-216
31. Dickinson L., Robinson L., Tjia J., Khoo S., and Back D. J. Chromatogr. B 829 (2005) 82-90
32. Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., and Decosterd L.A. J. Chromatogr. B 819 (2005) 259-276
33. Gehring A.-K., Mikus G., Haefeli W.E., and Burhnne J. Rapid Commun. Mass Spectrom. 21 (2007) 2704-2716
34. Notari S., Mancone C., Tripodi M., Narciso P., Fasano M., and Ascenzi P. J. Chromatogr. B 833 (2006) 109-116
35. Wang P.C., Wei J.S., Kim G., Chang M., and El-Shourbagy T. J. Chromatogr. A 1130 (2006) 302-307
36. Ehrhardt M., Mock M., Haefeli W.E., Mikus G., and Burhenne J. J. Chromatogr. B 850 (2007) 249-258
37. Estrela R.C., Ribeiro F.S., Seixes B.V., and Suarez-Kurtz G. Rapid Commun. Mass Spectrom. 22 (2008) 657-664
38. Guidance for Industry, Bionanlytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
39. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 75 (2003) 3019-3030
40. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), April 1996.